Renal and neurological side effects of colistin in critically ill patients

Abstract

Colistin is a complex polypeptide antibiotic composed mainly of colistin A and B. It was abandoned from clinical use in the 1970s because of significant renal and, to a lesser extent, neurological toxicity. Actually, colistin is increasingly put forward as salvage or even first-line treatment for severe multidrug-resistant, Gram-negative bacterial infections, particularly in the intensive care setting. We reviewed the most recent literature on colistin treatment, focusing on efficacy and toxicity issues. The method used for literature search was based on a PubMed retrieval using very precise criteria.Despite large variations in dose and duration, colistin treatment produces relatively high clinical cure rates. Colistin is potentially nephrotoxic but currently used criteria tend to overestimate the incidence of kidney injury. Nephrotoxicity independently predicts fewer cures of infection and increased mortality. Total cumulative colistin dose is associated with kidney damage, suggesting that shortening of treatment duration could decrease the incidence of nephrotoxicity. Factors that may enhance colistin nephrotoxicity (i.e., shock, hypoalbuminemia, concomitant use of potentially nephrotoxic drugs) must be combated or controlled. Neurotoxicity does not seem to be a major issue during colistin treatment. A better knowledge of colistin pharmacokinetics in critically ill patients is imperative for obtaining colistin dosing regimens that ensure maximal antibacterial activity at minimal toxicity.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 41

1. 1.

   Li J Nation RI Turnidge JD Milne RW Coulthard K Rayner CR Paterson DL Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsLancet Infect Dis2006 6589601

   Not in our library10.1016/s1473-3099(06)70580-1

2. 2.

   Levin AS Barone AA Penço J Santos MV Marinho IS Arruda EAG Manrique EI Costa SF Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClin Infect Dis1999 2810081011

   Not in our library10.1086/514732

3. 3.
   Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients · 2003

   No notice
4. 4.

   Garnacho-Montero J Ortiz-Leyba C Jiménez-Jiménez J Barrero-Almodovar AE Garcia-Garmendia JL Bernabeu-Wittell M Gallego-Lara SL Madrazo-Osuna J Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAPClin Infect Dis2003 3611111118

   Not in our library10.1086/374337

5. 5.

   Michaloupoulos AS Tsiodras S Rellos K Mentzelopoulos S Falagas ME Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibioticClin Microbiol Infect2005 11115121

   Not in our library10.1111/j.1469-0691.2004.01043.x

6. 6.
   Toxicity after prolonged (more than four weeks) administration of intravenous colistin · 2005

   No notice
7. 7.

   Kasiakou SK Michalopoulos A Soteriades ES Samonis G Sermaides GJ Falagas ME Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosisAntimicrob Agents Chemother2005 4831363146

   Not in our library10.1128/aac.49.8.3136-3146.2005

8. 8.

   Reina R Estenssoro E Saenz G Canales HS Gonzalvo R Vidal G Martins G Das Neves A Santander O Ramos C Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort studyIntensive Care Med2005 3110581065

   Not in our library10.1007/s00134-005-2691-4

9. 9.

   Petrosillo N Chinello P Proietti MF Cecchini L Masala M Franchi C Venditti M Esposito S Nicastri E Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse eventsClin Microbiol Infect Dis2005 11682683

   Not in our library10.1111/j.1469-0691.2005.01198.x

10. 10.

    Kallel H Bahloul M Hergafi L Akrout M Ketata W Chelly H Ben Hamida CB Rekik N Hammami A Bouaziz M Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICUInt J Antimicrob Agents2006 28366369

    Not in our library10.1016/j.ijantimicag.2006.07.008

11. 11.

    Koomanachai P Tiengrim S Kiratisin P Thamlikitkul V Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, ThailandInt J Infect Dis2007 11402406

    Not in our library10.1016/j.ijid.2006.09.011

12. 12.

    Betrosian AP Frantzeskaki F Xanthaki A Douzinas EE Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of mutidrug resistant Acinetobacter baumannii ventilator-associated pneumoniaJ Infect2008 56432436

    Not in our library10.1016/j.jinf.2008.04.002

13. 13.

    Bassetti M Repetto E Righi E Boni S Diverio M Molinari MP Mussap M Artioli S Ansaldi F Durando P Orengo G Bobbio Pallavicini F Viscoli C Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infectionsJ Antimicrob Chemother2008 61417420

    Not in our library10.1093/jac/dkm509

14. 14.

    Kallel H Hergafi L Bahloul M Hakim A Dammak H Chelly H Ben Hamida C Chaari A Rekik N Bouaziz M Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control studyIntensive Care Med2007 3311621167

    Not in our library10.1007/s00134-007-0675-2

15. 15.

    Falagas ME Fragoulis KN Kasiakou SK Sermaides GJ Michalopoulos A Nephrotoxicity of intravenous colistin: a prospective evaluationInt J Antimicrob Agents2005 26504507

    Not in our library10.1016/j.ijantimicag.2005.09.004

16. 16.

    Falagas ME Rafailidis PI Kasiakou SK Hatzopoulou P Michalopoulos A Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infectionsClin Microbiol Infect2006 1212271230

    Not in our library10.1111/j.1469-0691.2006.01559.x

17. 17.

    Pintado V Garcia San Miguel L Grill F Mejia B Cobo J Fortun J Martin-Davila P Moreno S Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteriaJ Infect2008 56185190

    Not in our library10.1016/j.jinf.2008.01.003

18. 18.

    Sabuda DM Laupland K Pitout J Dalton B Rabin H Louie T Conly J Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa.Can J Infect Dis Med Microbiol2008 19413418

    Not in our library10.1155/2008/743197

19. 19.

    Huang J Tang YQ Sun JY Intravenous colistin sulfate: A rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infectionsScand J Infect Dis2010 42260265

    Not in our library10.3109/00365540903490018

20. 20.

    Hartzell JD Neff R Ake J Howard R Olson S Paolino K Vishnepolsky M Weintrob A Wortmann G Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical centerClin Infect Dis2009 4817241728

    Not in our library10.1086/599225

21. 21.

    Kim J Lee KH Yoo S Pai H Clinical characteristics and risk factors of colistin-induced nephrotoxicityInt J Antimicrob Agents2009 34434438

    Not in our library10.1016/j.ijantimicag.2009.06.028

22. 22.

    Kwon JA Lee JE Huh W Peck KR Kim YG Kim DJ Oh HY Predictors of acute kidney injury associated with intravenous colistin treatmentInt J Antimicrob Agents2010 35473477

    Not in our library10.1016/j.ijantimicag.2009.12.002

23. 23.

    Cheng CY Sheng WH Wang JT Chen YC Chang SC Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infectionsInt J Antimicrob Agents2010 35297300

    Not in our library10.1016/j.ijantimicag.2009.11.016

24. 24.

    Song JY Lee J Heo JY Noh JY Kim WJ Cheong HJ Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumanniiInt J Antimicrob Agents2008 32281283

    Not in our library10.1016/j.ijantimicag.2008.04.013

25. 25.

    Falagas ME Rafailidis PI Ioannidou E Alexiou VG Matthaiou DK Karageorgopoulos DE Kapaskelis A Nikita D Michalopoulos A Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patientsInt J Antimicrob Agents2010 35194199

    Not in our library10.1016/j.ijantimicag.2009.10.005

26. 26.

    Kofteridis DP Alexopoulou C Valachis A Maraki S Dimopoulou D Georgopoulos D Samonis G Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control studyClin Infect Dis2010 5112381244

    Not in our library10.1086/657242

27. 27.

    DeRyke CA Crawford AJ Uddin N Wallace MR Colistin dosing and nephrotoxicity in a large community teaching hospitalAntimicrob Agents Chemother2010 5445034505

    Not in our library10.1128/aac.01707-09

28. 28.

    Lewis JR Lewis SA Colistin interactions with the mammalian urotheliumAm J Physiol Cell Physiol2004 286C913C922

    Not in our library10.1152/ajpcell.00437.2003

29. 29.
    Toxicity of polymyxins: a systematic review of the evidence from old and recent studies · 2006

    No notice
30. 30.
    Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group · 2004

    No notice
31. 31.

    Cruz DN Ricci Z Ronco C Clinical review: RIFLE and AKIN - time for reappraisalCrit Care2009 13211

    Not in our library10.1186/cc7759

32. 32.

    Koch-Weser J Sidel VW Federman EB Kanarek P Finer DC Eaton AE Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapyAnn Intern Med1970 72857868

    Not in our library10.7326/0003-4819-72-6-857

33. 33.

    Rattanaumpawan P Ungprasert P Thamlikitkul V Risk factors for colistin-associated nephrotoxicityJ Infect2011 62187190

    Not in our library10.1016/j.jinf.2010.11.013

34. 34.

    Joannidis M Druml W Forni LG Groeneveld AB Honore PM Oudemans-van Straaten HM Ronco C Schetz MR Woittiez AJ Critical Care Nephrology Working Group of the European Society of Intensive Care MedicinePrevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICMIntensive Care Med2010 36392411

    Not in our library10.1007/s00134-009-1678-y

35. 35.

    Parisi AF Kaplan MH Apnea during treatment with sodium colistimethateJAMA1965 194298299

    Not in our library10.1001/jama.194.3.298

36. 36.

    McQuillen MP Cantor HA O'Rourke JR Myasthenic syndrome associated with antibioticsTrans Am Neurol Assoc1967 92163167

    Not in our library

37. 37.

    Bulitta JB Yang JC Yohonn L Ly NS Brown SV D'Hondt RE Jusko WJ Forrest A Tsuji BT Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic modelAntimicrob Agents Chemother2010 5420512062

    Not in our library10.1128/aac.00881-09

38. 38.

    Markou N Markantonis SL Dimitrakis E Panidis D Boutzouka E Karatzas S Rafailidis P Apostolakos H Baltopoulos G Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled studyClin Ther2008 30143151

    Not in our library10.1016/j.clinthera.2008.01.015

39. 39.

    Plachouras D Karvanen M Friberg LE Papadomichelakis E Antoniadou A Tsangaris I Karaiskos I Poulakou G Kontopidou F Armaganidis A Cars O Giamarellou H Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteriaAntimicrob Agents Chemother2009 5334303436

    Not in our library10.1128/aac.01361-08

40. 40.

    Imberti R Cusato M Villani P Carnevale L Iotti GA Langer M Regazzi M Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after iv colistin methanesulfonate administrationChest2010 13813331339

    Not in our library10.1378/chest.10-0463

41. 41.

    Bergen PJ Li J Nation RL Turnidge JD Coulthard K Milne RW Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic modelJ Antimicrob Chemother2008 61636642

    Not in our library10.1093/jac/dkm511

Cited by papers we hold 2

• Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens · 2015
  No notice
• Antimicrobial Peptides for Gram-Negative Sepsis: A Case for the Polymyxins · 2012
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.